Hemodynamics and Immune Defense

Discoveries in Pharmacology, Volume 3

2nd Edition - October 23, 2023
Editors: Michael J. Parnham, Clive Page, Jacques Bruinvels
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 4 4 2 - 0
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 4 4 3 - 7

Haemodynamics and Immune Defence: Discoveries in Pharmacology, Second Edition, Volume Three presents selected articles from the historic Discoveries in Pharmacology… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Haemodynamics and Immune Defence: Discoveries in Pharmacology, Second Edition, Volume Three presents selected articles from the historic Discoveries in Pharmacology series that are enhanced with commentary from contemporary scholars who discuss the reception and importance of each chapter along with an updated bibliography on the subject and contributions from those involved in Nobel Prize winning discoveries and pioneering advancements in Pharmacology. This volume brings forth discussions on key discoveries in hemodynamics and immune defense, including chapters on penicillin by Dr. Selwyn and asthma by Dr. Brocklehurst.

Academic and industry researchers in pharmacology and medicine, as well as advanced students in the area, will find this useful teaching tool and launch to new discoveries. Chapters can also be used to supplement course material in pharmacology and medical courses. It will also be of interest to those who are interested in the history of medicine.

Cover image
Title page
Copyright
Contributors
Preface
Chapter 1A: Commentary on The discovery of beta adrenoceptor blocking drugs by Robert G. Shanks
Introduction
Selective β-adrenoceptor antagonists
Inverse agonism
Biased signaling
Expanded clinical uses
References
Chapter 1B: The control of blood pressure: The discovery of beta adrenoceptor blocking drugs
1.1 Introduction
1.2 Classification of adrenoceptors
1.3 Dichloroisoprenaline
1.4 Beta adrenoceptor blocking drugs in treatment of angina
1.5 The hypothesis of J.W. Black
1.6 Pronethalol
1.7 Propranolol
1.8 Ancillary properties of beta adrenoceptor antagonists
1.9 Practolol
1.10 Beta adrenoceptor blocking drugs in the treatment of hypertension
1.11 Beta adrenoceptor antagonists – research in other pharmaceutical companies 1959–1964
1.12 Conclusions
Acknowledgements
References
Chapter 2A: Can drugs be devised to lower elevated blood pressure by blocking sympathetic autonomic traffic? Commentary on Ganglion and adrenergic neurone-blocking agents by Alan L.A. Boura and Alan F. Green
Options for blockade of sympathetic autonomic traffic
Ganglion blockers: invention and aftermath
Adrenergic neurone blockers: invention and aftermath
Anti-hypertensive drugs after ganglion blockers and adrenergic neurone blockers
References
Chapter 2B: Peripheral anti-hypertensives: Ganglion and adrenergic neurone-blocking agents
2.1 Introduction
2.2 Ganglion blocking agents
2.3 Adrenergic neurone blockade
Acknowledgements
References
Chapter 3A: Commentary on The proliferation of non-steroidal anti-inflammatory drugs (NSAIDs) by T.Y. Shen
References
Chapter 3B: The proliferation of non-steroidal anti-inflammatory drugs (NSAIDS)
3.1 Introduction
3.2 The emergence of NSAIDS
3.3 The proliferation of isosteres and analogues
3.4 Unexpected clinical observations
Acknowledgement
References
Chapter 4A: Harry Collier: Scientist and visionary. Commentary on The story of aspirin by Harry O.J. Collier
A watershed discovery
COX isoforms
Unanswered questions
Other endogenous anti-inflammatory factors
References
Chapter 4B: The story of aspirin
4.1 Introduction
4.2 Seven stages of aspirin
4.3 Salicylate in rheumatism
4.4 Aspirin as a pro-drug for salicylate
4.5 Distinction between acetylsalicylate and salicylate
4.6 Aspirin opposes a local defensive process
4.7 Inhibition of prostaglandin synthase
4.8 Other sides of the story
4.9 New vistas for the use of aspirin
4.10 Summary and conclusions
References
Chapter 5A: Commentary on Histamine receptor antagonists by Madeleine Ennis and Wilfried Lorenz
H1 receptor antagonists
H2 receptor antagonists
H3 receptor antagonists
H4 receptor antagonists
Mast cell heterogeneity and responses to histamine receptor antagonists
Histamine diseases for histamine receptor antagonists—their place in anesthesia and surgery
Conclusion
References
Chapter 5B: Histamine receptor antagonists by Madeleine Ennis and Wilfried Lorenz
5.1 Discovery of H1-receptor antagonists
5.2 Detection of pharmacological effects of antihistamines other than those at H1-receptors
5.3 Discovery of histamine H2-receptors and their antagonists
5.4 Histamine receptor antagonists and histaminocytes – the mast cell heterogeneity
5.5 Histamine diseases for histamine receptor antagonists – their place in anaesthesia and surgery
Acknowledgement
References
Chapter 6A: Commentary on Asthma: A long and continuing story by Walter E. Brocklehurst
Introduction
Mediators of asthma
Mast cells in asthma
Other inflammatory cells
Cytokines as key mediators of asthma
Bronchodilators
The pivotal role of inhaled corticosteroids
Conclusions
References
Chapter 6B: Asthma: a long and continuing story
6.1 Introduction
6.2 Anaphylaxis, histamine and SRS-A
6.3 The pharmacology and identification of SRS-A
6.4 The central role of the mast cell
6.5 IgE – the underlying cause of asthma
6.6 The ebb and flow of the ‘Humoral theory'
6.7 Treatment of the asthmatic patient
References⁎
Chapter 7A: Commentary on From dyes to drugs by Robert Behnisch
Chemical matter for screening
Screening and mode of action
Pharmacology and regulation
Pharmacokinetics
Working culture
Reporting
Patent protection
Scientific recognition
Combination therapy
References
Chapter 7B: From dyes to drugs
7.1 Introduction: A brief history and nomenclature
7.2 Research 1927–1935
7.3 Dramatic changes 1937–1945
7.4 Sulphonamides substituted in the heterocyclic ring system
7.5 Standstill and renewal of research: Long-acting sulphonamides
7.6 Fields of study directly stemming from sulphonamide research
Acknowledgement
References
Chapter 8A: Development of β-lactams since 1986. Commentary on The discovery of penicillin and cephalosporins by Sydney Selwyn
Penicillins
Cephalosporins
Other β-lactams
Development of antibiotics for the present and future society
References
Chapter 8B: The discovery of penicillin and cephalosporins
8.1 Pre-scientific applications of ‘penicillin'
8.2 Scientific work on the ‘penicillin phenomenon'
8.3 The development of penicillin and its derivatives
8.4 The cephalosporins
Acknowledgements
References
Chapter 9A: Commentary on The antibiotic explosion by H. Boyd Woodruff and Richard W. Burg
References
Chapter 9B: The antibiotic explosion
9.1 Introduction
9.2 Historical implications
9.3 Major discoveries
9.4 The mode of action of antibiotics
9.5 Allied fields of science
9.6 Pharmacology
9.7 Toxicity
9.8 Antibiotics in agriculture
9.9 Non-antibiotic pharmacologically active fermentation products
9.10 The promise of the future
Acknowledgment
References
Index

Michael J. Parnham

Professor Michael J. Parnham, Ph.D., C.Biol.MRSB, FBPhS studied Pharmacology at Chelsea (now King's) College, gaining practical experience in the department of the subsequent Nobel Prize winner, John R. Vane, at the Royal College of Surgeons. With a PhD from Bristol University (1976), he carried out postdoctoral research on prostaglandins and chronic inflammation with Ivan Bonta at Erasmus University Rotterdam, The Netherlands. He established laboratories in pharmacology and toxicology and was Director of Preclinical Discovery working on novel anti-inflammatory macrolides at GSK from 2006. From 2012 to 2019, Prof. Parnham built up preclinical research in the Fraunhofer Institute of Molecular Biology & Applied Ecology IME. Dr. Parnham has published and lectured extensively and organised symposia on various aspects of immunopharmacology and anti-inflammatory therapy and in 2015, received a Lifetime Achievement Award from the International Association of Inflammatory Societies (IAIS). He is a scientific advisor to several companies.

Affiliations and expertise

Professor, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt am Main, Germany

Clive Page

Professor Clive P. Page, BSc PhD OBE HonFBPhS is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of and on boards of several companies. He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society. In 2017, Clive was awarded an OBE for Services to Pharmacology.

Affiliations and expertise

Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London, UK

Jacques Bruinvels

Professor Jacques Bruinvels, Ph.D. is Professor Emeritus of Pharmacology, Department of Pharmacology, Erasmus University Rotterdam, Rotterdam, The Netherlands. Full biography to follow

Affiliations and expertise

Professor Emeritus of Pharmacology, Department of Pharmacology, Erasmus University Rotterdam, Rotterdam, The Netherlands